image credit- freepik
10x Genomics, Inc., the life science technology leader focused on accelerating science and advancing human health, has announced that Fudan University Shanghai Cancer Center (FUSCC) and Shanghai Precision Diagnostics Co. Ltd (SPDx), will deploy its Xenium platform in a 24-month study.
The project seeks to identify biomarkers that may predict how patients with breast cancer respond to neoadjuvant therapy, or treatment administered before surgery to shrink tumors. FUSCC and SPDx intend to use the findings from the study to inform their development of potential future diagnostic approaches.
This study plans to analyse pretreatment tumour biopsy samples from 500 patients receiving neoadjuvant therapy. Researchers will use the Xenium platform, with the potential for future expansion to the Atera platform, to profile tumour gene expression of each tumour and compare those findings with treatment outcomes to identify cellular features and pathways associated with treatment response and resistance.
Earlier this year, 10x outlined its clinical strategy with two complementary paths for realising the potential of single cell and spatial technologies in diagnostics. One path is to enable customers to use 10x technologies in translational research that may inform the development of their own potential diagnostic approaches. The other is for 10x to directly advance selected diagnostic applications by generating the evidence that could support their future clinical use.
The FUSCC and SPDx study exemplifies the customer-driven path and complements academic collaborations in oncology that 10x announced earlier in the year.
